489 related articles for article (PubMed ID: 16177050)
21. Epigallocatechin Gallate Attenuates β-Amyloid Generation and Oxidative Stress Involvement of PPARγ in N2a/APP695 Cells.
Zhang ZX; Li YB; Zhao RP
Neurochem Res; 2017 Feb; 42(2):468-480. PubMed ID: 27889855
[TBL] [Abstract][Full Text] [Related]
22. [Research on EGCG improving the degenerative changes of the brain in AD model mice induced with chemical drugs].
He M; Liu MY; Wang S; Tang QS; Yao WF; Zhao HS; Wei MJ
Zhong Yao Cai; 2012 Oct; 35(10):1641-4. PubMed ID: 23627134
[TBL] [Abstract][Full Text] [Related]
23. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
Nunan J; Shearman MS; Checler F; Cappai R; Evin G; Beyreuther K; Masters CL; Small DH
Eur J Biochem; 2001 Oct; 268(20):5329-36. PubMed ID: 11606195
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Aβ aggregates in Alzheimer's disease by epigallocatechin and epicatechin-3-gallate from green tea.
Chen T; Yang Y; Zhu S; Lu Y; Zhu L; Wang Y; Wang X
Bioorg Chem; 2020 Dec; 105():104382. PubMed ID: 33137558
[TBL] [Abstract][Full Text] [Related]
25. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Gonçalves PB; Sodero ACR; Cordeiro Y
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606
[TBL] [Abstract][Full Text] [Related]
26. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
[TBL] [Abstract][Full Text] [Related]
27. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
28. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk between angiotensin and the nonamyloidogenic pathway of Alzheimer's amyloid precursor protein.
Kanarek AM; Wagner A; Küppers J; Gütschow M; Postina R; Kojro E
FEBS J; 2017 Mar; 284(5):742-753. PubMed ID: 28102934
[TBL] [Abstract][Full Text] [Related]
30. Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis.
Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM
BMC Neurosci; 2018 Jul; 19(1):46. PubMed ID: 30055565
[TBL] [Abstract][Full Text] [Related]
31. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Smith A; Giunta B; Bickford PC; Fountain M; Tan J; Shytle RD
Int J Pharm; 2010 Apr; 389(1-2):207-12. PubMed ID: 20083179
[TBL] [Abstract][Full Text] [Related]
32. Nardilysin prevents amyloid plaque formation by enhancing α-secretase activity in an Alzheimer's disease mouse model.
Ohno M; Hiraoka Y; Lichtenthaler SF; Nishi K; Saijo S; Matsuoka T; Tomimoto H; Araki W; Takahashi R; Kita T; Kimura T; Nishi E
Neurobiol Aging; 2014 Jan; 35(1):213-22. PubMed ID: 23954170
[TBL] [Abstract][Full Text] [Related]
33. ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways.
Steinhilb ML; Turner RS; Gaut JR
J Neurochem; 2002 Mar; 80(6):1019-28. PubMed ID: 11953452
[TBL] [Abstract][Full Text] [Related]
34. Measuring APP carboxy-terminal fragments.
Esposito LA
Methods Mol Biol; 2011; 670():71-84. PubMed ID: 20967584
[TBL] [Abstract][Full Text] [Related]
35. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
36. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
37. (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease.
Guo Y; Zhao Y; Nan Y; Wang X; Chen Y; Wang S
Neuroreport; 2017 Jul; 28(10):590-597. PubMed ID: 28520620
[TBL] [Abstract][Full Text] [Related]
38. Generation of Alzheimer's Disease Transgenic Zebrafish Expressing Human APP Mutation Under Control of Zebrafish appb Promotor.
Pu YZ; Liang L; Fu AL; Liu Y; Sun L; Li Q; Wu D; Sun MJ; Zhang YG; Zhao BQ
Curr Alzheimer Res; 2017; 14(6):668-679. PubMed ID: 27978793
[TBL] [Abstract][Full Text] [Related]
39. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
40. Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation.
Lin CL; Chen TF; Chiu MJ; Way TD; Lin JK
Neurobiol Aging; 2009 Jan; 30(1):81-92. PubMed ID: 17590240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
